An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK)

An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK)

2007 Eur J Cancer

Aballea, S. | Boler, A. | Craig, A. | Wasan, H. | Volume: 43, Issue: 11, Pages: 1687-93, Adolescent, Adult, Aged, Antineoplastic Agents/*therapeutic use, Chemotherapy, Adjuvant/economics, Colonic Neoplasms/drug therapy/*economics/surgery, Cost-Benefit Analysis, Female, Fluorouracil/administration & dosage/economics, Follow-Up Studies, Humans, Male, Middle Aged, Organoplatinum Compounds/administration & dosage/*economics, Prospective Studies, Quality-Adjusted Life Years, Treatment Outcome,

The MOSAIC study was the first trial to show a statistically significant disease-free survival benefit for a treatment regimen for stage III colon cancer in the adjuvant setting. At 4 years, there was a 25% reduction in the risk of disease recurrence in these patients for the combination of oxaliplatin/5-FU/FA compared with 5-FU/FA alone (p=0.002). This analysis evaluates the long-term cost effectiveness of oxaliplatin given in combination with 5-FU/FA from the perspective of the NHS in the United Kingdom (UK). The cost per quality-adjusted life-year gained over a lifetime was calculated using patient level data from the MOSAIC trial. Trial data were available for a median of 4 years of follow-up, these data were then extrapolated to a lifetime horizon. The estimated incremental lifetime cost per quality-adjusted life-year of oxaliplatin/5-FU/FA compared with 5-FU/FA alone in patients with stage III postoperative colon cancer is pound 4805. This compares favourably with other accepted interventions in oncology.

https://www.doi.org/10.1016/j.ejca.2007.05.001